Origin, Inc.
2 Research Way, Third Floor
Princeton
New Jersey
08540
United States
Tel: 609-250-6000
Website: https://www.originww.com
About Origin, Inc.
Origin, Inc. is a clinical-stage medtech company that incorporates its proprietary technology to deliver Nitric Oxide (NO) from a defined high-energy plasma stream to enhance and save lives. NO is a biologically active agent, with the ability to modify disease pathways through proven anti-microbial, anti-inflammatory, tissue-regenerative and vasodilatory activities. Origin’s technology will be initially applied to several highly unmet conditions, including the treatment of wounds, ulcers, and acute and chronic infections. Origin’s first potential product is a device focused on diabetic foot ulcers (DFU) a market estimated to be $13 billion2. Origin, Inc. (formerly Advanced Plasma Therapies, Inc.) was founded in 2010 and is based in Princeton, New Jersey.YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Michael Preston
JOBS:
Please click here for Origin job opportunities.
9 articles about Origin, Inc.
-
Origin, a 3D printing specialist for medical devices, just completed clinical trials and validation of its 3D-printed nasopharyngeal swabs for use in COVID-19 test kits. It is scaling up production and accepting orders to manufacture millions of the swabs.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
-
Origin files patent application to protect its proposed treatment for viral and bacterial respiratory infections
3/24/2020
Origin, Inc. announced that it has filed a provisional U.S. patent application to enhance the ability of its plasma-generated nitric oxide antimicrobial and antiviral therapy to be used to treat infections in the respiratory tract and other enclosed spaces in the body.
-
Origin applies to China regulatory agency for clinical pathway classification
10/28/2019
Origin, Inc. announced that it had applied to NMPA for classification of its plasma-generated nitric oxide device for the purposes of conducting clinical trials in Hong Kong and mainland China, and that NMPA had accepted its submission.
-
Henkel Joins Origin's Open Material Network to Enable New Chemistries for Additive Mass Production
2/4/2019
Henkel has joined Origin's Open Material Network and is already actively developing materials for Origin's open platform.
-
Proprietary Plasma-Generated Nitric Oxide Technology Being Developed at ADM Tronics for Origin Produces Positive Interim Results from Phase IIb Diabetic Foot Ulcer Study
10/26/2017
ADM Tronics Unlimited announced today that its client Origin has today announced positive interim results from its "GENESIS" US-based dose-ranging Phase IIb trial in the treatment of Diabetic Foot Ulcers utilizing a proprietary plasma technology.
-
Origin Announces Positive Interim Results from Phase IIb Dose-Ranging Study for Diabetic Foot Ulcers
10/26/2017
Origin has developed a proprietary technology which, for the first time, generates and delivers therapeutic quantities of plasma-generated nitric oxide into the tissue.
-
Origin, Inc. Announces First 50 Patients Randomized, And Full Site Activation In Phase IIb Dose-Ranging Study For Diabetic Foot Ulcers
6/1/2017
-
Origin, Inc. Announces First Randomized Patients Into Phase IIb-Equivalent Dose-Ranging Study In Diabetic Foot Ulcers
3/22/2017